ARS Pharmaceuticals Reports Security Holder Vote
Ticker: SPRY · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1671858
| Field | Detail |
|---|---|
| Company | Ars Pharmaceuticals, Inc. (SPRY) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
ARS Pharma shareholders voted on something important yesterday, details to follow.
AI Summary
ARS Pharmaceuticals, Inc. filed an 8-K on June 21, 2024, reporting on a matter submitted to a vote of its security holders on June 20, 2024. The filing does not disclose the specific outcome or details of the vote, only that it occurred.
Why It Matters
This filing indicates a significant event where shareholders voted on a matter, which could impact the company's future direction or governance.
Risk Assessment
Risk Level: medium — The filing is a procedural update about a shareholder vote, but the lack of detail on the vote's subject or outcome introduces uncertainty.
Key Players & Entities
- ARS Pharmaceuticals, Inc. (company) — Registrant
- June 20, 2024 (date) — Date of earliest event reported
- June 21, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What specific matter was submitted for a vote by ARS Pharmaceuticals' security holders?
The filing does not specify the exact matter that was submitted for a vote by security holders on June 20, 2024.
What was the outcome of the vote by ARS Pharmaceuticals' security holders?
The filing does not disclose the results or outcome of the vote that took place on June 20, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 20, 2024.
What is the principal executive office address for ARS Pharmaceuticals, Inc.?
The principal executive offices of ARS Pharmaceuticals, Inc. are located at 11682 El Camino Real, Suite 120, San Diego, California 92130.
Is ARS Pharmaceuticals, Inc. a new company or a former company with a name change?
The filing indicates that the company was formerly known as Silverback Therapeutics, Inc., with a name change date of April 12, 2016.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-06-21 17:00:55
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SPRY The Nasdaq
Filing Documents
- d815026d8k.htm (8-K) — 30KB
- 0001193125-24-165812.txt ( ) — 153KB
- spry-20240620.xsd (EX-101.SCH) — 3KB
- spry-20240620_lab.xml (EX-101.LAB) — 18KB
- spry-20240620_pre.xml (EX-101.PRE) — 11KB
- d815026d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 21, 2024 ARS Pharmaceuticals, Inc. By: /s/ Richard Lowenthal Name: Richard Lowenthal, M.S., MSEL Title: President and Chief Executive Officer